Abstract:AimMyeloid differentiation factor 88 (MyD88) plays a key role in tumor proliferation and metastasis. Targeting MyD88 is a potent strategy in tumor therapy. TJ‐M2010‐5 is a small molecule derivative of aminothiazole and could inhibit dimer formation of MyD88. To explore the potential of TJ‐M2010‐5 in tumor therapy, we determined its antitumor effect and correlate mechanisms of TJ‐M2010‐5 in hepatocellular carcinoma (HCC).MethodsThe antitumor effect of intratumoral injection of TJ‐M2010‐5 to H22 tumor‐bearing BALB/c mice was observed. Tumor growth was monitored. The expression of MyD88 and Ki‐67 were detected by immunofluorescence. In vitro, the impacts of TJ‐M2010‐5 on proliferation, cell cycle, necrosis, and apoptosis of H22 cells were evaluated. The direct and indirect effects of TJ‐M2010‐5 on macrophages were evaluated using flow cytometry.ResultsTJ‐M2010‐5 induced both G0/G1 and G1/S phase arrests in HCC cells. Mechanically, downstream activation of MyD88 was suppressed by TJ‐M2010‐5 through the extracellular regulated protein kinase‐1/2/p90 ribosomal S6 kinase/glycogen synthase kinase‐3β signaling pathway. In turn, cyclin‐dependent kinase (CDK)6/cyclin D1 and CDK2/cyclin E complexes were downregulated. More importantly, TJ‐M2010‐5 significantly inhibited tumor growth in mice. Additionally, the portion of antitumor M1 macrophages (F4/80+CD11c+) in the tumor microenvironment were increased after TJ‐M2010‐5 treatment. Together, these data indicate that TJ‐M2010‐5 is a promising therapeutic drug for HCC.ConclusionsThese results indicate that MyD88 is a feasible target for antitumor treatment and TJ‐M2010‐5 is a qualified candidate for HCC therapy.

Potent inhibition of the CD4-dependent T cell response by J2, a novel nonpeptide organic ligand of CD4 D1.

Immunosuppressive Effect of a Small Organic Compound J2

The Mechanism of Small Non-Peptidic Potential Inhibitor J2 by CFSE in Mice

A5, a New Small-Molecule Inhibitor of CD4 D1 Obtained from a Computer-Aided Screening Method, Contributes to the Inhibition of CD4+ T-cell Function

J2 prolongs the corneal allograft survival through inhibition of the CD4+ T cell-mediated response in vivo.

Modulating the Conformation of the TIR Domain by a Neoteric MyD88 Inhibitor Leads to the Separation of GVHD from GVT.

Beyond Knockout: A Novel Homodimerization-Targeting MyD88 Inhibitor Prevents and Cures Type 1 Diabetes in NOD Mice

Bioactive Peptide Design Based on Protein Surface Epitopes: A CYCLIC HEPTAPEPTIDE MIMICS CD4 DOMAIN 1 CC′ LOOP AND INHIBITS CD4 BIOLOGICAL FUNCTION

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Implication of Myeloid Differentiation Factor 88 Inhibitor TJ-M2010-5 for Therapeutic Intervention of Hepatocellular Carcinoma.

Immunomodulatory Activity of 3 Beta,6 Beta-Dihydroxyolean-12-En-27-Oic Acid in Tumor-Bearing Mice

Further Study on Molecular Biological Effects of Cd4 D1 Inhibitor J2 on Allografts Following Corneal Transplantation in Mice

An Organic CD4 Inhibitor Reduces the Clinical and Pathological Symptoms of Acute Experimental Allergic Encephalomyelitis

A Computer Screening Approach to Immunoglobulin Superfamily Structures and Interactions: Discovery of Small Non-Peptidic CD4 Inhibitors As Novel Immunotherapeutics.

A Jak2-selective Inhibitor Potently Reverses the Immune Suppression by Modulating the Tumor Microenvironment for Cancer Immunotherapy

Jaceosidin Inhibits Contact Hypersensitivity in Mice Via Down-Regulating IFN-γ/STAT1/T-bet Signaling in T Cells

(E)-1,3-diphenyl-1h-pyrazole Derivatives Containing O-benzyl Oxime Moiety As Potential Immunosuppressive Agents: Design, Synthesis, Molecular Docking and Biological Evaluation.

Synthetic Peptides Derived from the Fourth Domain of CD4 Antagonize CD4 Function and Inhibit T Cell Activation

Effect of a Cyclic Heptapeptide Based on the Human CD4 Domain 1 CC′ Loop Region on Murine Experimental Allergic Encephalomyelitis: Inhibition of Both Primary and Secondary Responses

Structure-based Virtual Screening and Characterization of a Novel IL-6 Antagonistic Compound from Synthetic Compound Database

5,2'-Dibromo-2,4,5-trihydroxydiphenylmethanone, a Novel Immunomodulator of T Lymphocytes by Regulating the CD4+ T Cell Subset Balance Via Activating the Mitogen-Activated Protein Kinase Pathway.